SSRIs For Depression Treatment In Adults: Usage & Side Effects Guide Released

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Mission Connection, a mental health provider that serves California, Virginia, and Washington, has released a guide on SSRIs and how they can work as a treatment for depression in adults.

-- Mission Connection has released a guide on selective serotonin reuptake inhibitors (SSRIs) and their applications for major depressive disorders in adults. The guide covers the mechanisms behind these medications, how to use them, and possible side effects users should be wary of.

For more information, please visit https://missionconnectionhealthcare.com/mental-health/antidepressants/ssri/

Per Mission Connection’s guide, SSRIs are a class of medications known as “second-generation” antidepressants, which carry a much lower risk of side effects than other groups of antidepressants. These drugs work by inhibiting the reabsorption of serotonin, a neurotransmitter responsible for regulating moods, sleep, and alertness—all of which play a role in how mental health conditions like depression manifest. The end result is higher levels of active serotonin in the brain, leading to improved moods, better focus, and a greater capacity to regulate emotions.

SSRIs do not work instantly, as the body requires time to adjust to them. Mission Connection explains that the medications can take between two and six weeks to begin taking effect, depending on the individual’s biology. However, the resource adds that SSRIs can be combined with talk therapy, holistic treatments, and lifestyle changes in an integrative treatment plan, which can improve the effectiveness of the medication.

Because SSRIs are generally well-tolerated, doctors may prescribe the drugs as a first line of treatment for patients considering medication options for depression. However, Mission Connection notes that there are still side effects that patients should be aware of. Gastrointestinal issues, headaches, dizziness, anxiety, sleep issues, and weight changes are all common, though not every user will experience them; more rarely, an individual may develop a life-threatening condition known as serotonin syndrome, but this is often the result of an overdose or combining SSRIs with substances that negatively interact with them.

Mission Connection also notes that abrupt cessation of SSRIs may lead to withdrawal symptoms, including the return of emotional and mental dysfunction, insomnia, sweating, brain jolts, and flu-like symptoms. To avoid withdrawal, the guide advises users to gradually reduce their dosage as directed by their healthcare provider or a mental health professional.

More information is available at https://missionconnectionhealthcare.com/

Contact Info:
Name: Nathan Di Tomaso
Email: Send Email
Organization: Mission Connection
Address: 30310 Rancho Viejo Rd. , San Juan Capistrano, California 92675, United States
Website: https://missionconnectionhealthcare.com/

Source: PressCable

Release ID: 89196883

Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  242.67
+0.97 (0.40%)
AAPL  308.63
+14.25 (4.84%)
AMD  517.82
-23.06 (-4.26%)
BAC  58.73
+0.37 (0.63%)
GOOG  356.18
-1.71 (-0.48%)
META  582.90
-30.01 (-4.90%)
MSFT  390.49
+6.21 (1.62%)
NVDA  194.83
-2.75 (-1.39%)
ORCL  140.27
-2.23 (-1.56%)
TSLA  393.45
-31.85 (-7.49%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.